Analyst Reco. Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Real-time Estimate Cboe BZX Other stock markets 03:35:11 2024-05-09 pm EDT			5-day change	1st Jan Change
139.6 ^USD	+0.42%		+0.08%	+6.21%

May. 08	Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	CI
May. 07	Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating	May. 02	MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating	May. 02	MT
Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170	Apr. 24	MT
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept	Apr. 08	MT
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating	Mar. 20	MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating	Mar. 13	MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating	Feb. 20	MT
Deutsche Bank Raises Neurocrine Biosciences Price Target to $161 From $160, Maintains Buy Rating	Feb. 08	MT
Citigroup Trims Price Target on Neurocrine Biosciences to $140 From $141, Maintains Neutral Rating	Feb. 08	MT
Mizuho Securities Raises Price Target on Neurocrine Biosciences to $140 From $116, Maintains Neutral Rating	Feb. 08	MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $140 From $127, Maintains Equalweight Rating	Feb. 08	MT
Wedbush Adjusts Neurocrine Biosciences' Price Target to $147 From $141, Keeps Outperform Rating	Jan. 29	MT
Goldman Sachs Raises Price Target on Neurocrine Biosciences to $153 From $134, Maintains Buy Rating	Jan. 25	MT
Barclays Raises Neurocrine Biosciences' Price Target to $150 From $145, Maintains Overweight Rating	Jan. 23	MT
RBC Raises Price Target on Neurocrine Biosciences to $129 From $121, Keeps Sector Perform Rating	Jan. 03	MT
Stifel Adjusts Price Target on Neurocrine Biosciences to $144 From $141, Maintains Buy Rating	Dec. 18	MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $127 From $110, Keeps Equalweight Rating	Dec. 13	MT
Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Buy Rating, $136 Price Target	Dec. 12	MT
UBS Adjusts Price Target on Neurocrine Biosciences to $128 From $135, Maintains Buy Rating	Nov. 13	MT
RBC Cuts Price Target on Neurocrine Biosciences to $121 From $128, Keeps Sector Perform Rating	Nov. 10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Analyst Reco.

Filters